<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02206295</url>
  </required_header>
  <id_info>
    <org_study_id>AC-065-108</org_study_id>
    <nct_id>NCT02206295</nct_id>
  </id_info>
  <brief_title>Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg</brief_title>
  <official_title>A Single-center, Open-label, Randomized, Two-period, Two-treatment, Crossover Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg (Reference Drug) or as Single Tablet of 1600 μg (Test Drug)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to demonstrate bioequivalence in the rate and extent of&#xD;
      absorption between 1600 μg selexipag test drug (administered orally as film-coated tablets of&#xD;
      1600 μg, twice a day (b.i.d.) and 1600 μg selexipag reference drug (administered orally as 8&#xD;
      film-coated tablets of 200 μg b.i.d.) at steady-state in healthy male subjects following a&#xD;
      multiple-dose up-titration scheme.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUCt) for selexipag</measure>
    <time_frame>23 days</time_frame>
    <description>Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. Selexipag will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. AUCt will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification during one dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration at steady state (Cmax,ss) for selexipag</measure>
    <time_frame>23 days</time_frame>
    <description>Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. Selexipag will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of selexipag will be used to directly obtain Cmax,ss.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUCt) for ACT-333679</measure>
    <time_frame>23 days</time_frame>
    <description>Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. ACT-333679 will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. AUCt will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification during one dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration at steady state (Cmax,ss) for ACT-333679</measure>
    <time_frame>23 days</time_frame>
    <description>Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. ACT-333679 will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of ACT-333679 will be used to directly obtain Cmax,ss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration at steady state (tmax,ss) for selexipag</measure>
    <time_frame>23 days</time_frame>
    <description>Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. Selexipag will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of selexipag will be used to directly obtain tmax,ss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration at the end of one dose interval (Ctrough) for selexipag</measure>
    <time_frame>23 days</time_frame>
    <description>Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. Selexipag will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of selexipag will be used to directly obtain Ctrough.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration at the end of one dose interval (Ctrough) for ACT-333679</measure>
    <time_frame>23 days</time_frame>
    <description>Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. ACT-333679 will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of ACT-333679 will be used to directly obtain Ctrough.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration at steady state (Ctrough,ss) for selexipag</measure>
    <time_frame>23 days</time_frame>
    <description>Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. Selexipag will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of selexipag will be used to directly obtain Ctrough,ss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration (Ctrough,ss) for ACT-333679</measure>
    <time_frame>23 days</time_frame>
    <description>Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. ACT-333679 will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of ACT-333679 will be used to directly obtain Ctrough,ss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure from baseline up to end of study</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Blood pressure and pulse rate will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure from baseline up to end of study</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Blood pressure and pulse rate will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulse rate from baseline up to end of study</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Blood pressure and pulse rate will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight from baseline up to end of study</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Blood pressure and pulse rate will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate from baseline up to end of study</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Heart rate will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PQ/PR interval (time interval from the beginning of the P wave to the beginning of the QRS complex) from baseline up to end of study</measure>
    <time_frame>up to 28 days</time_frame>
    <description>PQ/PR interval will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QRS interval (time interval from the beginning of the Q wave to the end of the S wave) from baseline up to end of study</measure>
    <time_frame>up to 28 days</time_frame>
    <description>QRS interval will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QT interval (time interval from beginning of the Q wave until end of the T wave) from baseline up to end of study</measure>
    <time_frame>up to 28 days</time_frame>
    <description>QT interval will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QTcB interval (time interval from beginning of the Q wave until end of the T wave, according to Bazett's correction) from baseline up to end of study</measure>
    <time_frame>up to 28 days</time_frame>
    <description>QT interval will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period. QTcB will be calculated according to the following formula (QTcB = QT/RR^0.5 where RR is 60/heart rate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QTcF interval (time interval from beginning of the Q wave until end of the T wave, according to Fridericia's correction) from baseline up to end of study</measure>
    <time_frame>up to 28 days</time_frame>
    <description>QT interval will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period. QTcF will be calculated according to the following formula (QTcF = QT/RR^0.33 where RR is 60/heart rate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent electrocardiogram abnormalities from baseline up to end of study</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Electrocardiogram abnormalities will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events leading to discontinuation of study treatment</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Adverse events will be considered as any adverse change from the subject's baseline condition that occurred during the course of the study. The subjects will be required to report any adverse events spontaneously. In addition, each subject will be assessed by the investigator at any measurement timepoint as well as at the end of observation and whenever necessary as deemed by the investigator.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence AB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Treatment A in Period 1 followed by Treatment B in Period 2. There will be a washout period lasting at least 6 days between treatments.&#xD;
Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.&#xD;
Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Treatment B in Period 1 followed by Treatment A in Period 2. There will be a washout period lasting at least 6 days between treatments.&#xD;
Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.&#xD;
Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selexipag</intervention_name>
    <arm_group_label>Treatment Sequence AB</arm_group_label>
    <arm_group_label>Treatment Sequence BA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent in the local language prior to any study-mandated procedure.&#xD;
&#xD;
          -  Healthy male subjects aged between 18 and 55 years (inclusive) at Screening.&#xD;
&#xD;
          -  No clinically significant findings on the physical examination at Screening.&#xD;
&#xD;
          -  Body mass index of 18.0 to 30.0 kg/m^2 (inclusive) at Screening.&#xD;
&#xD;
          -  Systolic blood pressure 100-145 mmHg, diastolic blood pressure 50-90 mmHg, and pulse&#xD;
             rate 45-90 beats per minute (all inclusive), measured at Screening.&#xD;
&#xD;
          -  12-lead electrocardiogram without clinically relevant abnormalities, measured at&#xD;
             Screening.&#xD;
&#xD;
          -  Hematology, clinical chemistry, and urinalysis test results not deviating from the&#xD;
             normal range to a clinically relevant extent at Screening.&#xD;
&#xD;
          -  Negative results from urine drug screen and alcohol breath test at Screening.&#xD;
&#xD;
          -  Ability to communicate well with the investigator, in the local language, and to&#xD;
             understand and comply with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergic reactions or hypersensitivity to selexipag or any excipient of the drug&#xD;
             formulation used in this study.&#xD;
&#xD;
          -  History or clinical evidence of any disease and/or existence of any surgical or&#xD;
             medical condition, which might interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of selexipag.&#xD;
&#xD;
          -  Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal&#xD;
             reactions.&#xD;
&#xD;
          -  Veins unsuitable for intravenous puncture on either arm (e.g., veins that are&#xD;
             difficult to locate, access or puncture; veins with a tendency to rupture during or&#xD;
             after puncture).&#xD;
&#xD;
          -  Treatment with selexipag or another investigational drug within 1 month prior to&#xD;
             Screening or 5 half-lives, whichever is longer.&#xD;
&#xD;
          -  History or clinical evidence of alcoholism or drug abuse within the 3-year period&#xD;
             prior to Screening.&#xD;
&#xD;
          -  Excessive caffeine consumption at Screening.&#xD;
&#xD;
          -  Smoking within 3 months prior to Screening and inability to refrain from smoking&#xD;
             during the course of the study.&#xD;
&#xD;
          -  Previous treatment with any prescribed medications (including vaccines) or&#xD;
             over-the-counter medications within 2 weeks prior to first study drug administration.&#xD;
&#xD;
          -  Loss of 500 mL or more of blood within 3 months prior to Screening.&#xD;
&#xD;
          -  Positive results from the hepatitis serology (hepatitis B antigen and hepatitis C&#xD;
             antibodies), except for vaccinated subjects or subjects with past but resolved&#xD;
             hepatitis, at Screening.&#xD;
&#xD;
          -  Positive results from the human immunodeficiency virus serology at Screening.&#xD;
&#xD;
          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect&#xD;
             full participation in the study or compliance with the protocol.&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity at Screening.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Baldoni, PhD, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QPS</name>
      <address>
        <city>Groningen</city>
        <zip>9713 AG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2014</study_first_posted>
  <last_update_submitted>July 30, 2014</last_update_submitted>
  <last_update_submitted_qc>July 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>selexipag</keyword>
  <keyword>ACT-333679</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selexipag</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02206295
org study id: AC-065-108
nct id: NCT02206295
lead sponsor: 
has dmc: No
The primary aim of this study is to demonstrate bioequivalence in the rate and extent of
      absorption between 1600 μg selexipag test drug (administered orally as film-coated tablets of
      1600 μg, twice a day (b.i.d.) and 1600 μg selexipag reference drug (administered orally as 8
      film-coated tablets of 200 μg b.i.d.) at steady-state in healthy male subjects following a
      multiple-dose up-titration scheme.
allocation: Randomized
intervention model: Crossover Assignment
masking: None (Open Label)
measure: Area under the plasma concentration-time curve (AUCt) for selexipag
time frame: 23 days
description: Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. Selexipag will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. AUCt will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification during one dosing interval.
measure: Maximum plasma concentration at steady state (Cmax,ss) for selexipag
time frame: 23 days
description: Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. Selexipag will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of selexipag will be used to directly obtain Cmax,ss.
measure: Area under the plasma concentration-time curve (AUCt) for ACT-333679
time frame: 23 days
description: Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. ACT-333679 will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. AUCt will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification during one dosing interval.
measure: Maximum plasma concentration at steady state (Cmax,ss) for ACT-333679
time frame: 23 days
description: Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. ACT-333679 will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of ACT-333679 will be used to directly obtain Cmax,ss.
measure: Time to reach maximum plasma concentration at steady state (tmax,ss) for selexipag
time frame: 23 days
description: Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. Selexipag will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of selexipag will be used to directly obtain tmax,ss.
measure: Trough plasma concentration at the end of one dose interval (Ctrough) for selexipag
time frame: 23 days
description: Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. Selexipag will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of selexipag will be used to directly obtain Ctrough.
measure: Trough plasma concentration at the end of one dose interval (Ctrough) for ACT-333679
time frame: 23 days
description: Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. ACT-333679 will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of ACT-333679 will be used to directly obtain Ctrough.
measure: Trough plasma concentration at steady state (Ctrough,ss) for selexipag
time frame: 23 days
description: Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. Selexipag will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of selexipag will be used to directly obtain Ctrough,ss.
measure: Trough plasma concentration (Ctrough,ss) for ACT-333679
time frame: 23 days
description: Blood will be collected by direct venipuncture or via an intravenous catheter placed in an arm vein after 4.5 days' treatment with 1600 μg selexipag b.i.d. during Treatments A and B. ACT-333679 will be quantified in plasma samples using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The measured individual plasma concentrations of ACT-333679 will be used to directly obtain Ctrough,ss.
measure: Change in systolic blood pressure from baseline up to end of study
time frame: up to 28 days
description: Blood pressure and pulse rate will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand).
measure: Change in diastolic blood pressure from baseline up to end of study
time frame: up to 28 days
description: Blood pressure and pulse rate will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand).
measure: Change in pulse rate from baseline up to end of study
time frame: up to 28 days
description: Blood pressure and pulse rate will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand).
measure: Change in body weight from baseline up to end of study
time frame: up to 28 days
description: Blood pressure and pulse rate will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand).
measure: Change in heart rate from baseline up to end of study
time frame: up to 28 days
description: Heart rate will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period.
measure: Change in PQ/PR interval (time interval from the beginning of the P wave to the beginning of the QRS complex) from baseline up to end of study
time frame: up to 28 days
description: PQ/PR interval will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period.
measure: Change in QRS interval (time interval from the beginning of the Q wave to the end of the S wave) from baseline up to end of study
time frame: up to 28 days
description: QRS interval will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period.
measure: Change in QT interval (time interval from beginning of the Q wave until end of the T wave) from baseline up to end of study
time frame: up to 28 days
description: QT interval will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period.
measure: Change in QTcB interval (time interval from beginning of the Q wave until end of the T wave, according to Bazett's correction) from baseline up to end of study
time frame: up to 28 days
description: QT interval will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period. QTcB will be calculated according to the following formula (QTcB = QT/RR^0.5 where RR is 60/heart rate).
measure: Change in QTcF interval (time interval from beginning of the Q wave until end of the T wave, according to Fridericia's correction) from baseline up to end of study
time frame: up to 28 days
description: QT interval will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period. QTcF will be calculated according to the following formula (QTcF = QT/RR^0.33 where RR is 60/heart rate).
measure: Number of treatment-emergent electrocardiogram abnormalities from baseline up to end of study
time frame: up to 28 days
description: Electrocardiogram abnormalities will be measured using standard 12-lead electrocardiography recorded at rest with the subject in the supine position for a 5 minute period.
measure: Number of participants with adverse events leading to discontinuation of study treatment
time frame: up to 28 days
description: Adverse events will be considered as any adverse change from the subject's baseline condition that occurred during the course of the study. The subjects will be required to report any adverse events spontaneously. In addition, each subject will be assessed by the investigator at any measurement timepoint as well as at the end of observation and whenever necessary as deemed by the investigator.
arm group label: Treatment Sequence AB
arm group type: Experimental
description: Subjects will receive Treatment A in Period 1 followed by Treatment B in Period 2. There will be a washout period lasting at least 6 days between treatments.
Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.
Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23.
arm group label: Treatment Sequence BA
arm group type: Experimental
description: Subjects will receive Treatment B in Period 1 followed by Treatment A in Period 2. There will be a washout period lasting at least 6 days between treatments.
Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.
Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23.
intervention type: Drug
intervention name: selexipag
arm group label: Treatment Sequence AB
arm group label: Treatment Sequence BA
criteria: 
gender: Male
minimum age: 18 Years
maximum age: 55 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Daniela Baldoni, PhD, PharmD
role: Study Director
affiliation: Actelion
facility: 
country: Netherlands
responsible party type: Sponsor
mesh term: Selexipag